Seven Recipharm OSD Facilities Sold to Blue Wolf Capital for New CDMO

• Recipharm has sold seven of its manufacturing and development facilities in Europe to Blue Wolf Capital, who will form a new CDMO company with the acquired sites.

• The divestment is part of Recipharm’s strategic plan to expand its biologics production capacity.

In a significant move that signals the ongoing reshaping of the Contract Development and Manufacturing Organisation (CDMO) industry, Recipharm has sold off seven of its manufacturing and development facilities in Europe. The buyer is the U.S. private equity firm, Blue Wolf Capital.

The facilities, located in Parets, Spain; Pessac, France; and five in Recipharm’s home country of Sweden (Hoganas, Karlskoga, Solna, Strangnas and Uppsala), have all been under Recipharm’s management for at least a decade. They are primarily focused on the development of oral solid, semi-solid and liquid dosage products and serve more than 120 customers worldwide.

This divestment is part of a larger strategic plan by Recipharm. The Stockholm-based company has expressed its intention to expand its biologics production capacity and position itself to capitalise on the increasing demand for cell and gene therapies. In line with this strategy, Recipharm also recently completed the spinout of its inhaler business, which includes three plants.

“Blue Wolf is excited for the opportunity to build a new CDMO platform with these seven European assets serving as a cornerstone,” said Shashank Patel, Principal at Blue Wolf. “Partnering with the leadership and teams at these seven facilities, we look forward to continuing to deliver world-class manufacturing capabilities and development services to our partners in order to provide the highest quality pharmaceuticals to patients around the world.”

Greg Behar, CEO, Recipharm said: “We are delighted that Blue Wolf has committed to acquire seven of our OSD sites, marking a significant step for both organisations. I am confident that Blue Wolf will continue to elevate service excellence and bolster the organisation for the benefit of customers and patients. By consolidating our site network, we are sharpening our focus on New Chemical Entities (NCEs), medium to high potency drugs, and on-patent medications within the oral solid dosage sector. This strategic divestment aligns with our overarching vision to emerge as the premier choice CDMO for both our customers and patients. I extend my best wishes to all our colleagues embarking on this new journey at those seven sites.”